ABSTRACT
We present a case of a patient with multiple sclerosis who was treated with plasmapheresis and valproic acid. We used therapeutic drug monitoring to determine whether plasma concentrations of valproic acid were kept within the therapeutic window and to determine the amount of valproic acid that was removed by plasmapheresis.
Subject(s)
Multiple Sclerosis/blood , Multiple Sclerosis/therapy , Plasmapheresis/methods , Valproic Acid/blood , Valproic Acid/therapeutic use , Anticonvulsants/blood , Anticonvulsants/therapeutic use , Drug Monitoring/methods , Humans , Male , Middle Aged , Multiple Sclerosis/drug therapyABSTRACT
After admitting a patient to our Neonatal Intensive Care with a severe anemia and an ear malformation, we ruled out any other cause than maternal medication use. Knowing she used mycophenolate mofetil during pregnancy, we looked for related articles. Two articles were found describing ear malformations, but no article was ever written about anemia caused by this medication. Consulting the international registers of drug effects through the National Institute for Public Health and the Environment, we found out that the anemia was never seen or reported before.
